Overview

Study in Taiwanese Subjects Identified as CYP2C19 Poor and Extensive Metabolizers Receiving Rosuvastatin

Status:
Completed
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to examine Taiwanese subjects identified as CYP2C19 poor and extensive metabolizers while taking single and multiple dosing a rosuvastatin calcium.
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca
Treatments:
Calcium
Calcium, Dietary
Rosuvastatin Calcium